Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

First-Ever Device for Fast and Virtually Painless Blood Draw Receives FDA Clearance

Seventh Sense Biosystems Inc. (7SBio) announced that a new blood collection device called TAP has received U.S. Food and Drug Administration 510(k) clearance. The technology represents a landmark innovation in the blood collection industry where one billion blood draws are performed each year for diagnostic testing.

Read More »

HealthSTAR Communications Expands its Strategic Offerings with Launch of HealthSTAR Fusion Group

HealthSTAR Communications announced the launch of HealthSTAR Fusion Group, an important new addition to its strategic network of companies.

Read More »

Results from recent Alzheimer’s disease trials validate the ProMIS approach

ProMIS Neurosciences announced it has issued a scientific white paper entitled “Results from recent Alzheimer’s disease trials validate the ProMIS approach.”

Read More »

Thermo Fisher did not infringe genetic-test patent

The U.S. Supreme Court cleared a subsidiary of biotech company Thermo Fisher Scientific Inc. of infringing a genetic-testing kit patent held by Promega Corp.

Read More »

Philips upbeat on prospects for new image-guided therapy platform

Philips announced the introduction of a new platform for image guided therapy that enables doctors to combine the use of several medical scanners, imaging data and large screen displays as they perform minimally invasive surgeries.

Read More »

CVS removes artificial trans fats from its food brands

CVS Health Corp. said its pharmacy chain had removed artificial trans fats, which have been linked to rising rates of heart diseases, from its store-branded food products well ahead of a June 2018 federal deadline.

Read More »

FDA Accepts NDA Resubmission for DEXTENZA

Ocular Therapeutix’s NDA resubmission for DEXTENZA 0.4 mg for ocular pain occurring after ophthalmic surgery was accepted as a filing for review by FDA.

Read More »

Massachusetts’ Agenus Quietly Discloses Failure of Cancer Vaccine Trial

Lexington, Mass.-based Agenus quietly filed with the U.S. Securities and Exchange Commission (SEC) that it was halting the company’s clinical trial of its cancer vaccine Prophage.

Read More »

Pfizer, Celgene, Eli Lilly, Merck & Co. CEOs and Other Execs Send Letter Supporting GOP Tax Plan

Chief executive officers from more 16 large manufacturing companies – including pharma leaders from Celgene, Dow Chemical, Eli Lilly, Merck and Pfizer – penned a letter to Congressional leaders in support of a Republican-backed tax reform plan.

Read More »

Serial Investor Carl Icahn Takes Stake in Bristol-Myers Squibb, Stock Jumps

Hours after Bristol-Myers Squibb announced a $2 billion stock buyback plan, billionaire investor Carl Icahn snapped up a “large stake” of BMS stock, which sent shares soaring.

Read More »

Kickstart Your GDPR Planning: Part 1

Join Lewis Barr, General Counsel and VP of Privacy at Janrain and Eleanor Treharne-Jones, VP Consulting at TRUSTe for the first installment of our General Data Protection Regulation (GDPR) webinar series.

Read More »

Kaiser Permanente Study Finds Testosterone Replacement Therapy Reduces Cardiovascular Risk Among Men with Androgen Deficiency

Men who used testosterone replacement therapy to treat symptoms of androgen deficiency had a 33 percent lower risk of cardiovascular events such as heart attacks and stroke compared to those who did not receive any hormone therapy. The findings from the Kaiser Permanente study were published in JAMA Internal Medicine.

Read More »

U.S. top court rejects patent licensing appeal

The U.S. Supreme Court turned away an appeal of a Maryland state court jury verdict ordering Boston Scientific Corp. to pay $308 million to a patent licensor.

Read More »

EP Vantage Releases its Annual Pharma and Medtech Sector Review Reports for 2016

For the world’s drug makers 2016 was a year of two halves. Dealmaking and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown. Meanwhile, the medtech sector demonstrated that greater efforts are needed to foster innovation if it is to thrive. These findings and more were released as part of the Pharma & Biotech 2016 in Review and Medtech 2016 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate.

Read More »

Data on Trevena’s opioid painkiller irks investors

Only some doses of Trevena’s experimental opioid painkiller were found as effective as morphine in two late-stage studies, though the drug met its main study goals.

Read More »

FDA rejects Amphastar’s nasal opioid overdose treatment

Amphastar Pharmaceuticals Inc. said the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the emergency opioid-overdose treatment, naloxone.

Read More »

This Tiny Biotech Grew 412% in 2016. A Look at Whether It Can Continue in 2017

Corbus Pharmaceuticals had a terrific 2016, with stock climbing 412 percent. Jim Crumly, writing for The Motley Fool, takes a look at the company and whether it can continue that trend for 2017.

Read More »

Sarepta Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead for $125 Million

Cambridge, Mass.-based Sarepta Therapeutics won a Rare Pediatric Disease Priority Review Voucher from the U.S. Food and Drug Administration when Exondys 51 was approved for Duchenne muscular dystrophy. The company announced that it had auctioned off its voucher for $125 million.

Read More »

Advancing New Healthcare Business Models: Accelerating Innovation

This webinar will focus on the importance of value proposition design (through the lens of the customer) and its applications to healthcare organizations. It will address how this is the foundational step for creating transformative healthcare business models. Participants will gain exposure to several design thinking tools that can be applied immediately.

Read More »

HBA Celebrates International Women’s Day: A Virtual Summit

The agenda will feature speakers who will share what achieving gender parity means to them, as well as highlight the groundbreaking work being done at large organizations.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom